Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 22Neoplasms 6Carcinoma, Hepatocellular 5Stomach Neoplasms 4Recurrence 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Cancer 4Uveal Melanoma 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Liver Neoplasms 3Colonic Neoplasms 3Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Hodgkin Disease 2Hematologic Neoplasms 2Glioma 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Basal Cell 2Brain Neoplasms 2

Interventions

pembrolizumab 10Nivolumab 9Ipilimumab 4avelumab 3Neoadjuvant Therapy 3toripalimab 2sintilimab 2durvalumab 2atezolizumab 2Specimen Handling 2Immune Checkpoint Inhibitors 2Celecoxib 2tislelizumab 1spartalizumab 1relatlimab 1regorafenib 1fludarabine phosphate 1fludarabine 1dostarlimab 1denileukin diftitox 1danvatirsen 1camrelizumab 1XELOX 1Taxes 1Surgical Procedures, Operative 1Radiation Dose Hypofractionation 1Paclitaxel 1Oxaliplatin 1Megestrol Acetate 1Medroxyprogesterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Turcot syndrome × relatlimab × Clear all
NCT03607890 2026-03-16

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
38 enrolled

Turcot syndrome, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡